Cell targeting startup Ability Biologics raises $12m in seed round

Ability was launched by Amplitude Ventures, working with co-founders Giles Day, CEO, and Jean-Philippe Bürckert, vice president of technology.

To read this article, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to read this article and more for free.

Share this